Recent studies showed that rituximab, a chimeric anti-CD20 monoclonal antibody, reduces antibody levels and ameliorates neuropathy in two thirds of patients with neuropathy and anti-myelin-associated glycoprotein (MAG) monoclonal IgM. Few data are available on the long-term effects of this therapy. We report on the long-term follow-up of rituximab responders with anti-MAG polyneuropathy.
No takes yet. Share an insight, caveat, or question.
Benedetti et al. (2008) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: